30 November 2021 in International Journal of Older People Nursing
Background: COVID‐19 is a threat to everyone's health and can be especially devastating to older individuals.Aim: This study examined the behavioural prevention practices against SARS‐CoV‐2 infection and the intention to vaccinate among older people when the COVID‐19 vaccine is on the verge of becoming available.Method: A cross‐sectional, online survey was conducted between 14th July and 8th October 2020 among the older people in Malaysia. A questionnaire was designed to assess the practice towards measures preventing SARS‐CoV‐2 infection, and COVID‐19 vaccination attitudes and intention. Socio‐demographic characteristics, constructs of a health belief model (HBM), the 6‐item state version of the State‐Trait Anxiety Inventory (STAI‐6) were correlates of the main outcomes.Findings: The mean score of total preventive measures scores was 13.4 ± 1.7 out of a maximum score of 15, indicating very good prevention practices. By demographics, females, having a tertiary education exhibited higher prevention practices in the univariable analyses. Components of the HBM and being female remain significant correlates of higher prevention practices in multivariable logistic regression analysis (MLRA). A total of 657 (87.1%) participants responded and intend to receive the COVID‐19 vaccination. Provider recommendations may improve vaccination uptake (91.6%). MLRA revealed that having a positive vaccination attitude was 16 times more likely to accept the COVID‐19 vaccination (OR = 16.10; 95% CI 8.97–28.91). Hearing of someone they know who has COVID‐19 serves as a cue to action and significantly influences vaccination (OR = 4.25; 95% CI 1.80–10.03). Participants below 70 years old expressed higher vaccination intention (OR = 2.07; 95% CI 1.19–3.58).Conclusion: The results provide the first evidence for public authorities to target older people vulnerable to compliance with recommended preventive measures against SARS‐CoV‐2 infections.
1 January 2026 in Case Reports in Infectious Diseases
Introduction: Motor complication in immunocompetent individuals with varicella zoster virus (VZV) reactivation is uncommon and may mimic a compressive spinal disorder. Case Presentation: A 77‐year‐old immunocompetent woman presented with an acute left foot drop preceded by coryzal symptoms and lower back pain. A vesicular rash developed over the left foot one week after the weakness began. Examination showed a predominantly severe left ankle dorsiflexion weakness with reduced sensation over the L5 and S1 dermatomes. A noncontrast magnetic resonance imaging (MRI) of the lumbosacral spine showed noncompressive degenerative changes. Cerebrospinal fluid (CSF) analysis showed lymphocytic pleocytosis, elevated protein, a reduced CSF‐to‐serum glucose ratio, and isolated VZV DNA on the polymerase chain reaction (PCR). VZV DNA was also detected from a vesicle swab. She received 14 days of intravenous acyclovir with neuropathic analgesia. A nerve conduction study and electromyography (NCS/EMG) at three months showed a severe left common peroneal neuropathy with sciatic nerve involvement. There was an initial slow motor recovery with persisting neuropathic pain, but only a residual moderate ankle dorsiflexion weakness remained at 9 months. Discussion: The combination of preceding radicular pain, vesicular rash, significant leg weakness, and positive VZV DNA in CSF and vesicle specimen supported a diagnosis of VZV‐associated meningoradiculitis. The NCS/EMG was consistent with an evolution of VZV involvement at multiple neuraxial levels into a predominantly peripheral neuropathy. This diagnosis is easily missed when radicular pain precedes or occurs without a rash and when imaging is disproportionate to the severity of deficit. CSF PCR and skin lesion sampling are central to an early diagnosis. Conclusion: VZV should be considered in patients with acute painful radiculopathy with significant limb weakness that is out of proportion to imaging findings, even without immunosuppression or an early rash. Early antiviral therapy can limit disability, although residual neurological deficits and pain may persist.